shutterstock_713156257_-jacob-lund
Jacob Lund / Shutterstock.com
20 May 2019EuropeMichael Pears and Joel Beevers

SPCs: extending protection lifespan

Supplementary protection certificates (SPCs) are intended to ensure that medicinal products requiring marketing authorisation (MA) are adequately protected. They safeguard a sufficient return for, and thereby incentivise, pharmaceutical research involving significant pre-clinical and clinical work. Such work can include not only the development of new active ingredients per se, but also new inventions involving existing active ingredients.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
12 February 2026   The court has denied a German non-practising entity’s bid to secure unitary protection for a patent that it has asserted against Intel.
Europe
12 February 2026   UK and European patent attorneys share their initial views after the UK Supreme Court delivered its landmark judgment, which “brings some much‑needed clarity and consistency” to the patentability of AI-related innovations—including those in the medtech industry.
Europe
12 February 2026   The patent community rejoices after the UK Supreme Court's Emotional Perception decision aligns the UK with Europe, paving the way for computer tech companies to protect inventions—including those in the medtech industry.